Company Directory / research
PrivateFor profitresearchParis, France
Inotrem
Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock.
- Founded
- 2013 13 years ago
- Staff
- 11-50 band, as listed
- Followers
- - on LinkedIn
- Funding
- $121M as listed, currency not stated
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed
Age
13 years old.
Reach
Website ranked #14,370,481 in the world for traffic, about 48 visits a month.
What it does
BiotechnologyHealth CareMedical
Funding, as listed
$121M currency not stated
- Rounds8
- LatestSeries unknown, Nov 2023
- Investors10, 8 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Inotrem, field by field. Contact details are held but never shown.
The company
- Name
- Inotrem
- Type
- For profit
- Status
- Private
- Founded
- 2013
- Founders
- Jean-Jacques Garaud, Marc Derive
- Industry
- research
- Categories
- Biotechnology, Health Care, Medical
Where
- City
- Paris
- Country
- France
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 11-50
- Web traffic rank
- #14,370,481
- Monthly web visits
- 48
Funding, as listed
- Total
- 121,000,000 (currency not stated)
- Rounds
- 8
- Latest round
- Series unknown
- Latest round date
- Nov 2023
- Investors
- 10
- Lead investors
- 8
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Inotrem may be growing as it has successfully reached an agreement with the FDA for a Phase 3 registration trial for its product Nangibotide in septic shock. This advancement indicates progress in the company's product pipeline and a significant step towards potential market entry. The achievement of this regulatory milestone suggests that Inotrem is advancing its clinical development, which is a critical aspect of growth in the biotechnology industry. Furthermore, the initiation of a Phase 3 trial typically involves a substantial investment in research and development, implying that Inotrem is allocating resources towards its core business activities.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in France.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 88,142 companies in France and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.